Xeris Biopharma Holdings, Inc. XERS Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
- Xeris Biopharma Holdings, Inc. (XERS) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of $1K in Q1 2026.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
- Over 2 years (2022 to 2024), Xeris Biopharma Holdings, Inc.'s other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax has grown at a -100.0% compound annual growth rate (CAGR), from $1K to $0.